Compare BGS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGS | MGNX |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.1M | 280.3M |
| IPO Year | 2004 | 2013 |
| Metric | BGS | MGNX |
|---|---|---|
| Price | $2.93 | $4.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.90 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.9M | 396.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | ★ 83.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,828,687,000.00 | $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.52 | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.87 | $1.30 |
| 52 Week High | $6.38 | $5.08 |
| Indicator | BGS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 26.91 | 50.96 |
| Support Level | N/A | $3.85 |
| Resistance Level | $3.75 | $4.50 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 9.42 | 42.50 |
B&G Foods Inc manufactures, sells, and distributes a range of branded, shelf-stable, and frozen food and household products across the United States, Canada, and Puerto Rico. Its products include frozen and canned vegetables, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, and wine vinegar. The company's main brands include Crisco, Clabber Girl, Bear Creek, Polaner, Underwood, B&G, Grandma's, New York Style, B&M, Baker's Joy, Regina, TrueNorth, Static Guard, SugarTwin and Brer Rabbit. It operates in four reportable segments: i) Specialty, the majoriy revenue generating segment, ii) Meals, iii) Frozen & Vegetables, iv) Spices & Flavor Solutions.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.